NCT01280526COMPLETEDanonymous

A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas

Sponsor

Source record

The Lymphoma Academic Research Organisation

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Indication / condition

AI-normalized

Peripheral T Cell Lymphoma

Intervention

Source record

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Source & freshness

Source record

NCT ID

NCT01280526

Original source

ClinicalTrials.gov

Source last updated

May 22, 2014

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01280526

Title

A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas

Sponsor

The Lymphoma Academic Research Organisation

Status

COMPLETED

Phase

PHASE1

Condition raw

Peripheral T Cell Lymphoma

Condition normalized

Peripheral T Cell Lymphoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Target normalized

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Interventions

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Public preview

Source record

This study is an open label, multicenter study with two phases:

A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma.

An expansion phase in order to assess the safety and the efficacy of the association of the recommended dose of Romidepsin associated with CHOP in a population of patients with T-cell lymphoma.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01280526

Status

COMPLETED

Phase

PHASE1

Sponsor

The Lymphoma Academic Research Organisation

Executive brief

Investment-Ready Snapshot

This study is an open label, multicenter study with two phases: * A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma. * An expansion phase in order to assess the safety and the efficacy of the association of the recommended dose of Romidepsin associated with CHOP in a population of patients with T-cell lymphoma.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 22, 2014

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01280526

Indication

Peripheral T Cell Lymphoma

Modality

small molecule

Target

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Intervention

Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.